Newsroom

Articles

Mini-Lab presentation at ECCMID 2022 in Lisbon

MSF and the Mini-Lab team were present at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which took place in Lisbon, Portugal from 23 to 26 April 2022.

Read more
Articles

The Mini-Lab is deployed in Aweil, South Sudan in April 2022

The Mini-Lab has been deployed in Aweil, South Sudan in April 2022.

Read more
Masques Compressifs Haiti. Tabarre
Articles

In Haiti, the MSF Foundation launches a research study on compression masks, the first of its kind in the medical world

Read more
Articles

Dr Nada Malou's intervention at the DIHAD 2022 conference

DIHAD is considered the first humanitarian and development event in the Middle East and has been bringing together leading humanitarian actors, government emergency management agencies, foundations and others since 2004. On the occasion of the 18th conference held from March 14-16, 2022, Dr Nada Malou presented Antibiogo.

 

Read more
Articles

Launch of the internal deployment plan

Mini-Lab is now ready to be deployed within the MSF Movement.

Read more
KoutialaLab
Vidéos

Antibiogo launch of the latest clinical evaluation in Mali

Headline

Antibiogo 3
Articles

Antibiogo ISO 13485 Certified, a First for a Humanitarian Project

In 2025, the Antibiogo application is seeing wide deployment, extending beyond MSF field operations. After being adopted by all MSF laboratories in 2024, the tool has also been integrated by local health authorities in several countries: Burkina Faso, Comoros, Guinea, Liberia, Mali, Central African Republic, Democratic Republic of the Congo, and Benin. This expansion marks a new era for Antibiogo: scaling up.

At the same time, the project team continued efforts to reach the highest level of quality standards, culminating in obtaining ISO 13485 certification. This unprecedented level of requirement for an NGO project reflects the excellence of the management practices implemented for this medical device project, for which MSF Foundation is the legal manufacturer.

Read more

MSF Foundation in Video

News

Publications

  • Publications

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more
  • Publications

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more

Press Review

No news for now.